Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...